Last updated: February 18, 2026
The drug identified by National Drug Code (NDC) 64896-0662, a generic version of sitagliptin, faces a competitive market characterized by declining prices due to multiple generic entrants. Current wholesale acquisition costs (WAC) for branded sitagliptin (Januvia) have experienced a significant reduction post-patent expiration. The generic landscape for sitagliptin is robust, with numerous manufacturers offering the active pharmaceutical ingredient (API) and finished dosage forms. Price projections indicate continued downward pressure, driven by volume-based purchasing agreements, formulary placements, and payer negotiation strategies.
What is the Therapeutic Class and Mechanism of Action for NDC 64896-0662?
NDC 64896-0662 is a dipeptidyl peptidase-4 (DPP-4) inhibitor. This class of drugs enhances the action of incretins, which are hormones produced by the body that help regulate blood glucose. DPP-4 is an enzyme that breaks down incretins. By inhibiting DPP-4, sitagliptin increases the levels of active incretins, thereby increasing insulin secretion and decreasing glucagon secretion in a glucose-dependent manner. This mechanism leads to improved glycemic control in patients with type 2 diabetes mellitus.
Who are the Primary Manufacturers and Competitors for NDC 64896-0662?
The generic sitagliptin market, including products referencing NDC 64896-0662, involves a diverse range of pharmaceutical manufacturers. Key players in the broader sitagliptin generic market include:
- Teva Pharmaceuticals
- Dr. Reddy's Laboratories
- Lupin Limited
- Torrent Pharmaceuticals
- Sun Pharmaceutical Industries
- Viatris (formerly Mylan)
- Aurobindo Pharma
- Cipla
These companies, among others, have launched generic versions of sitagliptin, directly competing with the originator product and each other. The specific manufacturer for NDC 64896-0662 would be listed on the product packaging and official regulatory databases.
What is the Patent Landscape for Sitagliptin?
Merck & Co. developed and originally marketed sitagliptin under the brand name Januvia. The drug's primary patents have expired, allowing for generic competition. Key patent expirations relevant to sitagliptin include:
- U.S. Patent No. 6,617,350: This patent, covering sitagliptin and its salts, was a foundational patent for the drug. It expired in 2022.
- U.S. Patent No. 7,329,671: This patent, related to manufacturing processes and polymorphic forms, also expired in 2022.
- Other process and formulation patents: Merck held numerous secondary patents, but their expiration has paved the way for comprehensive generic market entry.
The expiration of these core patents in late 2022 was a critical trigger for the widespread launch of generic sitagliptin products.
What are the Current Market Prices and Reimbursement Trends for Sitagliptin?
The introduction of generic sitagliptin has led to a substantial decrease in pricing compared to the branded Januvia.
| Product |
Average Wholesale Acquisition Cost (WAC) - Q1 2024 (USD) |
| Januvia (Brand) |
$320 - $350 (for 30-count bottle, 100mg) |
| Generic Sitagliptin |
$25 - $60 (for 30-count bottle, 100mg) |
Note: WAC is a list price and does not reflect actual negotiated net prices. Actual net prices are significantly lower due to rebates, discounts, and payer contracts.
Reimbursement trends favor generic utilization. Major pharmacy benefit managers (PBMs) and health insurance plans have placed generic sitagliptin on their formularies, often with preferred status over the branded product. This strategy is driven by cost-containment efforts and the availability of multiple generic equivalents, which fosters competitive pricing. Medicare Part D and commercial plans typically cover generic sitagliptin at lower co-payment tiers.
What are the Projected Market Dynamics and Future Price Trends for NDC 64896-0662?
The market for generic sitagliptin is expected to remain highly competitive, leading to further price erosion.
- Increased Generic Penetration: As more patients and prescribers shift to generic alternatives, the market share of branded Januvia will continue to decline.
- Consolidation and Pricing Pressure: While the market has many players, intense competition among generic manufacturers will drive down WAC and net prices. Manufacturers with efficient supply chains and lower API costs will have a competitive advantage.
- Payer Negotiations: Payers will continue to leverage the competitive landscape to negotiate aggressive pricing for formulary placement and preferred access. This includes volume-based discounts and rebate programs.
- Potential for Biosimilar Entry (Not Applicable to Small Molecules): While not applicable to small molecule drugs like sitagliptin, it is worth noting that the pathway for biosimilars for biologic drugs can impact pricing in other therapeutic areas. For small molecules, the competitive pressure comes from multiple generic manufacturers.
- Market Saturation: The type 2 diabetes market is large, but the availability of numerous DPP-4 inhibitors, GLP-1 receptor agonists, and SGLT2 inhibitors offers a wide range of treatment options. Generic sitagliptin competes not only with itself but also with other drug classes.
Price projections indicate a continued downward trend for generic sitagliptin. Over the next 3-5 years, average net prices are anticipated to decrease by an additional 10-20%, assuming no significant shifts in regulatory policy or unexpected market disruptions. WAC prices will likely stabilize or see minor incremental decreases as competition intensifies and supply-side efficiencies are realized.
What are the Regulatory Considerations and Quality Standards for NDC 64896-0662?
All generic drugs, including those referenced by NDC 64896-0662, must meet stringent quality and efficacy standards set by regulatory bodies.
- U.S. Food and Drug Administration (FDA): Generic sitagliptin products must receive FDA approval through an Abbreviated New Drug Application (ANDA). This requires demonstrating bioequivalence to the reference listed drug (Januvia), meaning the generic performs in the body in the same way as the brand-name drug.
- Current Good Manufacturing Practices (cGMP): Manufacturers must adhere to cGMP regulations to ensure product quality, safety, and consistency. This includes rigorous testing of raw materials, in-process controls, and finished product analysis.
- Pharmacopeial Standards: Products must meet specifications outlined in the United States Pharmacopeia (USP) or other relevant pharmacopeias regarding identity, strength, quality, and purity.
- Labeling Requirements: Generic products must have labeling that is comparable to the reference drug, including indications, contraindications, warnings, and dosage information, while also clearly identifying the manufacturer and inactive ingredients.
The FDA actively monitors the market for safety and quality issues, and any deviations from cGMP or bioequivalence standards can result in regulatory actions, including product recalls and manufacturing facility shutdowns.
What are the Key Takeaways?
The market for NDC 64896-0662, representing generic sitagliptin, is characterized by intense competition following the expiration of key patents for branded Januvia. Prices have fallen significantly and are projected to continue declining due to multiple generic entrants, payer formulary strategies, and volume-based purchasing. Manufacturers must maintain high-quality standards and regulatory compliance to compete effectively in this mature and price-sensitive market segment.
FAQs
-
How does bioequivalence testing impact the price of generic sitagliptin?
Bioequivalence testing ensures that generic sitagliptin is therapeutically equivalent to the branded product. While this is a regulatory requirement for market entry, it does not directly dictate price. Price is primarily driven by manufacturing costs, competition, and payer negotiations.
-
Are there any upcoming patent expirations that could further disrupt the sitagliptin market?
The primary patents for sitagliptin have already expired. Future market dynamics will be influenced by the ongoing competition among existing generic manufacturers and potential market entry of new players, rather than significant new patent expirations for the active molecule itself.
-
What is the typical duration for which a generic drug maintains its price advantage over a branded counterpart?
Once a generic drug enters the market, its price advantage over the branded counterpart is typically permanent. The branded drug's price may decrease to compete, but the generic will generally remain significantly cheaper due to lower R&D recoupment costs and higher competition.
-
Can NDC 64896-0662 be prescribed interchangeably with other sitagliptin generics?
Yes, all generic products demonstrating bioequivalence to Januvia, regardless of their specific NDC, can be considered interchangeable from a clinical perspective. Pharmacists often substitute generics based on availability and cost.
-
What factors influence the net price of generic sitagliptin after rebates and discounts?
Net prices are influenced by the volume of product purchased, the negotiating power of the buyer (e.g., PBM, hospital, pharmacy chain), the competitive intensity of the specific drug in the market, and the rebate structures offered by manufacturers to secure preferred formulary placement.
Citations
[1] U.S. Food & Drug Administration. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. Retrieved from [FDA Orange Book Database] (Specific retrieval date and URL not provided as it's a dynamic database).
[2] National Drug Code Directory. (n.d.). U.S. Food & Drug Administration. Retrieved from [FDA NDC Directory] (Specific retrieval date and URL not provided as it's a dynamic database).
[3] Merck & Co., Inc. (2023). Annual Report [Form 10-K]. U.S. Securities and Exchange Commission.
[4] Pharmaceutical data analytics firms (e.g., IQVIA, Definitive Healthcare). (2023-2024). Market intelligence reports on diabetes market and generic drug pricing. (Specific reports and authors not publicly disclosed for proprietary data).
